162 related articles for article (PubMed ID: 21193424)
1. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.
Trecarichi EM; Tumbarello M; Caira M; Candoni A; Cattaneo C; Pastore D; Fanci R; Nosari A; Vianelli N; Busca A; Spadea A; Pagano L
Haematologica; 2011 Jan; 96(1):e1-3; author reply e4. PubMed ID: 21193424
[No Abstract] [Full Text] [Related]
2. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies.
Todeschini G; Franchini M; Tecchio C; Meneghini V; Pizzolo G; Veneri D; Murari C; Ricetti MM; Perona G
Int J Infect Dis; 1998-1999 Winter; 3(2):99-104. PubMed ID: 10225988
[TBL] [Abstract][Full Text] [Related]
3. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection.
Suárez C; Peña C; Gavaldà L; Tubau F; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e73-8. PubMed ID: 20223693
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
Tofas P; Samarkos M; Piperaki ET; Kosmidis C; Triantafyllopoulou ID; Kotsopoulou M; Pantazatou A; Perlorentzou S; Poulli A; Vagia M; Daikos GL
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):335-341. PubMed ID: 28529091
[TBL] [Abstract][Full Text] [Related]
5. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
[TBL] [Abstract][Full Text] [Related]
6. A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.
Fernández-Cruz A; Alba N; Semiglia-Chong MA; Padilla B; Rodríguez-Macías G; Kwon M; Cercenado E; Chamorro-de-Vega E; Machado M; Pérez-Lago L; García de Viedma D; Díez Martín JL; Muñoz P
Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530598
[TBL] [Abstract][Full Text] [Related]
7. Acute Inflammatory Response of Patients with Pseudomonas aeruginosa Infections: A Prospective Study.
Gómez-Zorrilla S; Morandeira F; Castro MJ; Tubau F; Periche E; Cañizares R; Dominguez MA; Ariza J; Peña C
Microb Drug Resist; 2017 Jun; 23(4):523-530. PubMed ID: 27754817
[TBL] [Abstract][Full Text] [Related]
8. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
[TBL] [Abstract][Full Text] [Related]
9. Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.
Gudiol C; Albasanz-Puig A; Laporte-Amargós J; Pallarès N; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo M; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Paz Morales H; Brunel AS; García E; Isler B; Kern WV; Morales I; Maestro-de la Calle G; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmatti P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Carratalà J;
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015035
[TBL] [Abstract][Full Text] [Related]
10. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.
Hakki M; Lewis JS
Infection; 2018 Jun; 46(3):431-434. PubMed ID: 29460229
[TBL] [Abstract][Full Text] [Related]
13. Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.
Recio R; Villa J; Viedma E; Orellana MÁ; Lora-Tamayo J; Chaves F
Int J Antimicrob Agents; 2018 Aug; 52(2):172-179. PubMed ID: 29621591
[TBL] [Abstract][Full Text] [Related]
14. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
[TBL] [Abstract][Full Text] [Related]
15. Increased risk of death with recurrent Pseudomonas aeruginosa bacteremia.
McCarthy KL; Paterson DL
Diagn Microbiol Infect Dis; 2017 Jun; 88(2):152-157. PubMed ID: 28366610
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
Microb Drug Resist; 2005; 11(1):68-74. PubMed ID: 15770098
[TBL] [Abstract][Full Text] [Related]
18. An 18-case outbreak of drug-resistant Pseudomonas aeruginosa bacteriemia in hematology patients.
Micol JB; de Botton S; Guieze R; Coiteux V; Darre S; Dessein R; Leroy O; Yakoub-Agha I; Quesnel B; Bauters F; Beaucaire G; Alfandari S
Haematologica; 2006 Aug; 91(8):1134-8. PubMed ID: 16885056
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections.
Suárez C; Peña C; Tubau F; Gavaldà L; Manzur A; Dominguez MA; Pujol M; Gudiol F; Ariza J
J Infect; 2009 Apr; 58(4):285-90. PubMed ID: 19297028
[TBL] [Abstract][Full Text] [Related]
20. Integrating rapid diagnostics and antimicrobial stewardship improves outcomes in patients with antibiotic-resistant Gram-negative bacteremia.
Perez KK; Olsen RJ; Musick WL; Cernoch PL; Davis JR; Peterson LE; Musser JM
J Infect; 2014 Sep; 69(3):216-25. PubMed ID: 24841135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
